title: Emesis control by aprepitant in children and adolescents with chemotherapy.
abstract: BACKGROUND
  Chemotherapy-induced nausea and vomiting (CINV) is a feared adverse reaction during cancer treatment. Aprepitant has shown to be effective for CINV in adults, but little is known on its effect in pediatrics. So far, the drug is not licensed in this population.
  
  
  OBJECTIVE
  To investigate efficacy of aprepitant in children and young adolescents with high or moderate emetogenic courses, with uncontrollable emesis in previous cycles.
  
  
  METHODS
  Retrospective, observational study in children and adolescents treated with aprepitant at Ghent University Hospital, Belgium. Antiemetic regimens and emesis control were analyzed.
  
  
  RESULTS
  Twenty patient charts representing 104 chemotherapy cycles were reviewed. Complete vomiting control was observed in 10 patients (50 %), representing 89/104 (85.6 %) episodes. Incomplete vomiting control was observed in 10 patients (50 %), representing only 15 episodes (14.4 %). Of these episodes with incomplete vomiting control, 6 were in acute phase (40 %), 7 in delayed phase (46.7 %) and 2 in both acute and delayed phase (13.3 %).
  
  
  CONCLUSIONS
  Aprepitant might be effective in preventing or reducing vomiting in children. When combined with standard antiemetics, aprepitant was well tolerated. In attendance of results of on-going international clinical trials, our results encourage us to continue the use of aprepitant after failure of emesis control in previous cycles.
authors.affiliation: Department of Pharmacy, Ghent University Hospital, -1 K12, De Pintelaan 185, 9000, Ghent, Belgium, tiene.bauters@uzgent.be.
authors.forename: Tiene G M
authors.initials: TG
authors.lastname: Bauters
authors.forename: Joris
authors.initials: J
authors.lastname: Verlooy
authors.forename: Hugo
authors.initials: H
authors.lastname: Robays
authors.forename: Yves
authors.initials: Y
authors.lastname: Benoit
authors.forename: Geneviève
authors.initials: G
authors.lastname: Laureys
mesh_terms: D000293:Adolescent; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077608:Aprepitant; D001530:Belgium; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; D000077608:Aprepitant